LCP1 and osteosarcoma: Studies focused on BMSC-exos in various cancer types demonstrated variable results, for example, overexpression of the exosomal protein lymphocyte cytosolic protein 1 (LCP1) from BMSCs promoted osteosarcoma growth via the JAK2/STAT3 pathway, while simultaneously suppressing the tumor suppressor miR-135a-5p [56].